January 16, 2024
2 min watch
Save
VIDEO: Gene therapy has potential to reduce injection burden
Issue: March 10, 2024
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
WAILEA, Hawaii — In this Healio Video Perspective from Retina 2024, David A. Eichenbaum, MD, discusses the potential for gene therapy to reduce the intravitreal injection treatment burden in retinal disease.
“The concept is that we’re going to patients that have the highest burden and change the cells inside their eyes to become biofactories to produce therapeutic proteins that could, theoretically, reduce the frequency of treatment profoundly in patients who require a lot of intravitreal injections,” Eichenbaum said.
Published by:
Sources/Disclosures
Collapse
Source:
Eichenbaum D. Gene therapy: The good, the bad and the maybe. Presented at: Retina 2024; Jan. 13-19, 2024; Wailea, Hawaii.
Disclosures:
Eichenbaum reports being an investigator and consultant for multiple gene therapy companies including, Gyroscope, Janssen, Regenxbio and 4DMT.
Read more about
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.